Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Classical hematology 1CNS 1

Conditions

Lymphoma 58Multiple Myeloma 52Leukemia 48Leukemia, Myeloid, Acute 44Precursor Cell Lymphoblastic Leukemia-Lymphoma 41Myelodysplastic Syndromes 37Lymphoma, Non-Hodgkin 37Hodgkin Disease 36Lymphoma, Mantle-Cell 26Lymphoma, Large B-Cell, Diffuse 26Leukemia, Lymphocytic, Chronic, B-Cell 25Lymphoma, Follicular 22Breast Neoplasms 22Burkitt Lymphoma 21Lymphoma, B-Cell, Marginal Zone 16Congenital Abnormalities 15Lymphoma, Large-Cell, Immunoblastic 14Recurrence 13Leukemia, Myelogenous, Chronic, BCR-ABL Positive 13Sarcoma 12Neoplasms, Plasma Cell 12Hematologic Neoplasms 10Leukemia, Myelomonocytic, Juvenile 9Leukemia, Biphenotypic, Acute 9Blast Crisis 9Neoplasms 8Myeloproliferative Disorders 8Leukemia, Myelomonocytic, Chronic 8Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 7Neuroblastoma 7

Interventions

Radiotherapy 2Pyridoxine 2Etoposide 2Cytarabine 2Cyclophosphamide 2sodium thiosulfate 1pegfilgrastim 1pegaspargase 1etoposide phosphate 1Vincristine 1Triptorelin Pamoate 1Rituximab 1Prednisolone 1Methylprednisolone 1Methotrexate 1Mercaptopurine 1Leucovorin 1Hydrocortisone 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Doxorubicin 1Dexrazoxane 1Dexamethasone 1Celecoxib 1Carboplatin 1Capecitabine 1Asparaginase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Drug-Related Side Effects and Adverse Reactions × Filgrastim × Clear all
NCT00074165 2023-07-06

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

OHSU Knight Cancer Institute

Phase 2 Terminated
17 enrolled 7 charts
CNSClassical hematologyLymphoid

Lymphoma, Thrombocytopenia, Central Nervous System Neoplasms, Intraocular Lymphoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡